Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial
Authors:
- Rasmus Blechingberg FriisRFRasmus Blechingberg Friis
- Helle PappotHPHelle Pappot
- Niels Henrik HjollundNHNiels Henrik Hjollund
- Marianne Ingerslev HoltMHMarianne Ingerslev Holt
- Kim WedervangKWKim Wedervang
- Malene Martini ClausenMCMalene Martini Clausen
- Karin Holmskov HansenKHKarin Holmskov Hansen
- Susanne Oksbjerg DaltonSDSusanne Oksbjerg Dalton
- 1 June 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (6) , 813-823
Abstract
PURPOSE: Remote symptom monitoring of patients with cancer has previously shown potential for improving clinical outcomes. This study aimed to evaluate the effects of remote symptom monitoring in patients with lung cancer after palliative induction treatment. METHODS: In a Danish multicenter randomized controlled trial, patients were randomly assigned 1:1 to remote symptom monitoring (intervention arm) added to standard of care versus standard of care (control arm). Key eligibility criteria were stage III-IV lung cancer (small cell lung cancer and non–small cell lung cancer), Eastern Cooperative Oncology Group performance status ≤2, and no sign of disease progression after initial induction treatment. Patients in the intervention arm completed a weekly electronic questionnaire, assessing 14 common symptoms related to lung cancer. When a patient reported a severity exceeding a predefined threshold, the patient was subsequently contacted by phone to address potential clinical needs. Symptom monitoring was discontinued after progression. The primary outcome was overall survival (OS). Secondary measures included assessment of health-related quality of life (HRQoL). RESULTS: Of 494 randomly assigned patients, 240 were assigned to the intervention arm and 254 were assigned to the control arm. At a median follow-up of 3.5 years, symptom monitoring did not significantly improve OS compared with standard care (hazard ratio [HR], 0.93 [95% CI, 0.75 to 1.16]; P = .53). Exploratory subgroup analyses indicated improved survival for patients treated with carboplatin/vinorelbine (HR, 0.67 [95% CI, 0.45 to 0.98]; P = .04) and in departments with previous implementation of patient-reported outcomes (HR, 0.66 [95% CI, 0.44 to 0.98]; P = .04). HRQoL analyses did not reveal clinically meaningful effects. CONCLUSION: In the Danish health care system, remote symptom monitoring did not improve OS but led to modest improvements in HRQoL for patients with advanced lung cancer.Keywords
This publication has 55 references indexed in Scilit:
- Patient-Reported Outcome Measures in Cancer CareJAMA Network Open, 2024
- Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic CancerJAMA, 2022
- Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer ImmunotherapyJAMA Network Open, 2022
- The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysisCancer Medicine, 2020
- Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung CancerJAMA, 2019
- Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literatureSupportive Care in Cancer, 2018
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Detection of lung cancer relapse using self-reported symptoms transmitted via an Internet Web-application: pilot study of the sentinel follow-upSupportive Care in Cancer, 2014
- The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional studySupportive Care in Cancer, 2013
- Reporting of Patient-Reported Outcomes in Randomized TrialsJAMA, 2013